Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review

Ajeet Kumar1*, Pankaj Bhatt1, Nitesh Mishra2
1Vivek College of technical Education, BIJNOR, U.P, India, 246701.
2Mankind Pharma Pvt. Ltd. Gurgaon, India, 110038.
*Corresponding author: E-Mail: ajeet0703bph@gmail.com

ABSTRACT

Irritable Bowel Syndrome (IBS) is a typical disorder affecting countless around the globe. Around 5% to 25% all out masses encounters Irritable bowel disorder. It is as of now seen as the most broadly perceived bowel disorder. Irritable gut syndrome (IBS) might be a typical gastrointestinal disorder described by stomach torment (swelling, stomach distension, and impression of fragmented departure) and detachment of the bowels, blockage or exchanging diarrhoea and stoppage.

Right now, alosetron complex (Lotronex®), a specific monoamine synapse type 3 receptor rival, is that the main medicine endorsed for the treatment of extreme diarrhoea-dominating irritable gut syndrome (IBS-D) in women who have deficiently had run of the mill restorative consideration. Alosetron has incontestable effectuality contrasted and fake treatment in clinical preliminaries and has been appeared to improve generally speaking wellbeing related personal satisfaction (HRQoL). Despite the fact that the effectiveness and favourable position of alosetron has been obviously illustrated, it’s been utilized meagrely since its presentation. This transient audit portrays the historical backdrop of alosetron, effectiveness of alosetron inside the treatment of IBS, the effect of extreme IBS on HRQoL, wellbeing issues, the possibility investigation and alleviation methodology program underneath that alosetron is as of now endorsed, and a report on post advancing data.

KEY WORDS: Irritable bowel syndrome, diarrhoea, 5-HT3 antagonist, alosetron hydrochloride, Excipients.

1. INTRODUCTION

Irritable Bowel Syndrome (IBS) is a typical issue that influences a large number of individuals around the globe. As of late, new ideas have risen with respect to the pathophysiology of IBS. These ideas incorporate modification of intestinal motility, unnecessary development of microbes in the small digestive tract, infinitesimal irritation, instinctive excessive touchiness and changes in the intestinal pivot. This developing worldview could permit probiotic remedial open doors for IBS.

About 5% to 25% of the total populace experience the ill effects of irritable bowel syndrome (IBS). It is currently perceived as the most widely recognized intestinal turmoil. To characterize the SII, the Rome criteria are created. As per these criteria, the beginning of stomach agony or inconvenience related with changes in intestinal propensities and cluttered poop is analysed as IBS. Gastro oesophageal reflux ailment (GERD), the nearness of indigestion and corrosive spewing forth, has been tried by 20% of the overall public at any rate once per week and 44% at any rate once per month. As per late examinations, there gives off an impression of being a solid cover among GERD and IBS. This cover every now and again happens; in this manner, the commonness of IBS was a lot higher in patients with GERD than in patients without GERD. Then again, up to 30% of patients with IBS had reflux manifestations (Pourhoseingholi, 2012).

History and Stigma: Irritable bowel syndrome (IBS or spastic colon) is a conclusion dependent on side effects portrayed by ceaseless stomach torment, issue and swelling and adjusted bowel propensities. As a useful bowel issue, IBS does not have a known natural reason. The runs or stoppage may prevail. Generally, an analysis of prohibition,
a finding of IBS should now be possible just based on manifestations, without caution attributes, for instance more noteworthy than age starting 50 years, weight reduction, and naturally visible hematocentia, foundational indications of contamination or colitis or family ancestry of provocative bowel malady. The beginning of IBS is bound to happen after disease (post-irresistible, IBS-PI), an upsetting life occasion or the beginning of development. In spite of the fact that there is no solution for IBS, there are medicines that endeavour to lighten side effects, including dietary changes, drugs, and mental intercessions.

**Epidemiology:** IBS is the most well-known gastrointestinal confusion (GI). In epidemiological examinations, the commonness detailed IBS changes, however this is for the most part because of contrasts in indicative criteria. The overall commonness of IBS among grown-ups is evaluated at 10-20% (Hungin, 2005). Albeit a large portion of the commonness figures are from the Western populace the expanding information uncover that the syndrome is so predominant in non-Western social orders like China, the South Korea, India and Malaysia. Then again, it ought to be noticed that in any event the urban territories of these nations are quickly westernized. The pervasiveness of IBS in Africa is ineffectively seen, yet information from Kenya and Nigeria show predominance rates of somewhere in the range of 8% and 33% (Ladep, 2007). By and large, there is an unmistakable female predominance among patients with IBS. Among the general population looking for human services administrations, ladies are driving men in the finding of IBS in a proportion of 4:1, while the dissemination seems, by all accounts, to be under 2:1 of commonness information dependent on network reviews. The conceivable clarifications for sexual orientation contrasts are social and social issues, for example, the conduct of looking for restorative consideration and the physiological contrasts identified with sex in intestinal capacity and agony affectability. Rather than Western social orders, IBS gives off an impression of being fundamentally more pervasive among men than ladies in India. This was proposed to reflect social contrasts in the look for restorative consideration and openness. IBS can influence individuals of all ages, yet the condition is analyzed all the more regularly somewhere in the range of 20 and 40 years, while GI natural illnesses prevail in individuals more than 60 (Bennet, 2002). Irritable bowel syndrome may likewise show up in youth, however information on pervasiveness are rare. In certain reports, IBS is analyzed in 6-14% of school-age youngsters and 22% to 45% of kids matured 4-18 who go to tertiary consideration facilities.

**Types of IBS:** IBS is regularly grouped into four subtypes as per the standard consistency of an individual's stool. The four subtypes of IBS are:
- IBS with stoppage (IBS-C)
- Hard or cumbersome stools at any rate 25% of the time
- Stool broke down or watered under 25% of the time
- IBS with the runs (SII-D)
- Faeces free or water at any rate 25% of the time
- Strep or hard stools under 25% of the time

**Blended SII (IBS-M):**
- Hard or cumbersome stools at any rate 25% of the time
- Faeces free or water at any rate 25% of the time (Caplan, 2005).

**IBS subtype (IBS-U):** Strep or hard stools under 25% of the time Stool broke up or watered under 25% of the time.

**Figure 2. Bristol Stool Chart**

**Symptoms:** Serotonin (5-hydroxytryptamine) is a vital synapse in the enteric sensory system (ENS, with its abbreviation), the peristaltic reflex (specifically 5-HT4 receptor), intestinal pivot and vaginal and instinctive pathways or pathways for the most part influencing 5-HT3 receptors. 5-HT assumes a key job in the adjustment of numerous intestinal capacities, for example, motility, sensation, blood stream and emission. In people, the most elevated amount of explicit restricting has been found in the amygdales, which are a fundamental piece of passionate reactions to instinctive incitement. Adversaries of 5-HT3 and 5-HT4 agonists have shown viability and adequacy in the treatment of various or worldwide IBS indications. The models of medications were alosetron and tegaserod (Camilleri, 2009).

**Treatment:** The refreshed treatment suggestions for irritable bowel syndrome are introduced in the Rome III assent
stool recurrence and improve the general condition of ladies with IBS-D. A meta-investigation inferred that alosetron emphatically impacts torment and distress in ladies without stoppage, however that the job of alosetron in male patients isn't clear (Ceremoni, 2003).

**Alosetron Hydrochloride:** Alosetron was presented in mid 2000 for the treatment of ladies with IBS-D, yet willfully reviewed around the same time because of reports of uncommon however genuine unfavourable occasions related with its utilization, especially ischemic colitis (IC) and stoppage entanglements (CoC), which included fecalomas, intestinal obstacle, poisonous megacolon, and intestinal aperture (Chang, 2006).

After the withdrawal, the US Food Administration (FDA, for its abbreviation in English) and the medications got various solicitations from the two patients and specialists to come back to the market alosetron (Horton, 2001). Patients getting alosetron must consent to the patient-specialist arrangement structure, report unfriendly occasions and have the chance to take an interest in a deliberate study. At long last, drug specialists must affirm that the program mark is connected to a remedy for alosetron before administering the medication and giving a prescription manual for alosetron (Ameen, 2008).

**Drug Profile:** Alosetron HCl

![Figure 3](image)

**Figure 3. Chemical structure of Alosetron hydrochloride**

| Category | Serotonin Antagonists, Gastrointestinal Agents |
|----------|-----------------------------------------------|
| IUPAC name | 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H,2H,3H,4H, 5H- pyrido[4,3-b]indol-1-one |
| Mol. Formula | C17H18N4O.HCl |
| Mol. Mass | 330.81 |
| Colour | White |
| Odour | Odourless |
| Taste | Bitter |
| Melting point | 288-291°C |
| Solubility | Freely soluble in water (1 g in approximately 8 ml water), sparingly soluble in ethanol (95%); slightly soluble in chloroform; very slightly soluble in ether. |

**Pharmacokinetics:**

**Absorption:** Alosetron is quickly assimilated after oral organization with a mean total bioavailability of around 50% to 60% (inexact range 30% to >90%). After organization of radio marked Alosetron, just 1% of the portion was recuperated in the defecation as unaltered medication. After oral organization of a 1 mg alosetron portion, a pinnacle plasma centralization of roughly 5 ng/mL in Men and 9 ng/mL in Women happens at 60 minutes.

**Food Effects:** The ingestion of alosetron is decreased by about 25% by associative organization with nourishment, with a normal deferral after some time to achieve the greatest convergence of 15 minutes.

**Distribution:** Alosetron exhibits a volume of conveyance of around 65-95 L. Plasma protein restricting is 82% in a fixation scope of 20 to 4000 ng/ml

**Digestion:** Alosetron is widely utilized in people. Around 73% of the portion was recouped in the pee and 24% of the portion was recuperated in the defecation. Just 7% of the portion was recouped as a medication without adjustment. No less than 13 metabolites were recognized in the pee. The overwhelming item in the pee was the 6-hydroxy metabolite (15% of the portion). This metabolite was used optionally to a glucuronide that was additionally present in the pee (14% of the portion). Little measures of 6-hydroxy and 6-O-glucuronide metabolites are additionally found in the defecation. A bispyoxylated dichloronyl spoke to 14% of the portion and its monorbonyl antecedent spoke to another 4% in the pee and 6% in the excrement. No other urinary metabolites represented over 4% of the portion.

Alosetron is processed by human microsomal cytochrome P450 (CYP) and includes 2C9 (30%), 3A4 (18%) and 1A2 (10%) proteins. Additionally the metabolic change of stage 1 not intervened by CYP adds to about 11%. Be that as it may, CYP1A2 assumes an increasingly vital job in the digestion of alosetron.

**Elimination:** The oral portion of alosetron two times per day does not deliver collection. The end half-existence of alosetron is 1.5 hours (plasma freedom is roughly 600 ml/min). Pharmacokinetic examination of the populace in
patients with IBS affirmed that the leeway of the alkosome is negligibly impacted by portions up to 8 mg. renal disposal of alosetron without changes represents just 6% of the portion. Renal freedom is around 94 ml/min.

Pharmacodynamics:

Mechanism of action: Alosetron is a powerful and particular 5-HT3 receptor opponent. 5 HT3 receptors are cationic channels actuated by the ligand that are broadly appropriated in enteric neurons in the human gastrointestinal tract, just as in other fringe and focal areas. The initiation of these channels and the subsequent neuronal depolarization impact the guideline of instinctive torment, travel of the colon and gastrointestinal emissions identified with the pathophysiology of irritable bowel syndrome (IBS). The 5-HT3 receptor rival, for example, alosetron, hinders the initiation of non-particular cationic channels that reason adjustment of the enteric sensory system.

IBS is portrayed by instinctive touchiness and by a hyperactivity of the gastrointestinal tract, which prompts an irregular vibe of torment and engine movement. Patients with IBS experience the ill effects of general torment and distress contrasted with sound volunteers. After this unwinding, alosetron decreased overstated torment and engine reactions, likely because of bar of 5-HT3 receptors.

Figure 4. Blocking of 5HT3 receptor

Indication: Alosetron is expected to be indicated for the treatment of irritable bowel syndrome (IBS) in female patients who are not constipation predominant.

Usual dosage ranges: 0.5 mg-1.0 mg

Infants and Children: Safety and efficacy have not been established

Adults: 1 mg twice daily

Indication: Alosetron ought to be shown for the treatment of irritable bowel syndrome (IBS) in female patients who are not dominating of constipation.

Normal measurement ranges: 0.5 mg-1.0 mg

New born children and kids: security and adequacy have not been set up

Grown-ups: 1 mg two times per day.

Lactation: It isn't known whether alosetron is disseminated in human bosom milk. Be that as it may, alosetron is discharged in the milk of lactating rodents. Alert ought to be practiced when alosetron is given to a lady who is bosom sustaining.

Pregnancy: FDA Pregnancy Category B

Negative effects: The most widely recognized antagonistic occasions are: Ischemic colitis; Constipation; Pain.

Contraindications: Incessant or extreme constipation, squeals of constipation, Obstruct intestinal impediment, stenosis, harmful megacolon, aperture and/or gastrointestinal attachments.

- Colonic ischemic colitis, modification of intestinal flow, thrombophlebitis or hypercoagulability.

Crohn's malady or ulcerative colitis:
- Diverticulitis
- Hypersensitivity to any segment of the item.

Medication associations:
- Fluvoxamine
- Ketoconazole
- Isoniazide
- Procaainamide

Capacity: Store at 25°C (77°F); Excursions permitted somewhere in the range of 15 and 30°C (59 and 86°F)

Excipient Profile:

Lactose Anhydrous: Non-proprietary Names

BP : Anhydrous Lactose
JP : Anhydrous Lactose
PhEur : Lactose, Anhydrous
USP-NF: Anhydrous Lactose
**Table.2. Details of Lactose Anhydrous**

| Synonyms                        | Lactopress Spray-Dried; SuperTab 11SD; SuperTab 14SD |
|---------------------------------|------------------------------------------------------|
| Chemical Name                   | Spray-dried lactose is a mixture of amorphous lactose, which is a 1:1 mixture of α- and β-lactose, and O-b-D-galactopyranosyl-(1→4)-a-D-glucopyranose monohydrate |
| Molecular Formula               | C12H22O11 (for amorphous)                            |
|                                 | C12H22O11.H2O (for monohydrate)                      |
| Molecular Weight                | 342.30 (for amorphous)                              |
|                                 | 360.31 (for monohydrate)                            |
| Functional Category             | Directly compressible tablet excipient; tablet and capsule diluents; tablet and capsule filler. |
| Description                     | Lactose occurs as white to off-white crystalline particles or powder. It is odorless and slightly sweet-tasting. Spray-dried direct compression grades of lactose are generally composed of 80–90% specially prepared pure α-lactose monohydrate along with 10–20% of amorphous lactose. |
| Density (bulk)                  | 0.60 (g/cm³)                                        |
| Density (tapped)                | 0.71 (g/cm³)                                        |
| Solubility                      | Soluble in water; sparingly soluble in ethanol (95%) and ether; 40 g/100mL at 25°C for typical Sheffield Pharma Ingredients products. |
| Stability and Storage Conditions| Spray-dried lactose should be stored in a well-closed container in a cool, dry place. |
| Incompatibilities               | Lactose is a reducing sugar. The amorphous lactose, which is the most reactive form of lactose present in spray-dried lactose, will interact more readily than conventional crystalline grades. Typical reactions include the Maillard reaction with either primary or secondary amines. |
| Safety                          | Lactose is widely used in pharmaceutical formulations as diluents in oral capsule and tablet formulations. Adverse reactions to lactose are largely due to lactose intolerance, which occurs in individuals with a deficiency of the enzyme lactase. |
| Regulatory Status               | GRAS listed.                                         |

**Lactose Monohydrate:** Non-proprietary Names: (BP: Lactose; PhEur: Lactose Monohydrate; JP: Lactose Hydrate; USP-NF: Lactose Monohydrate)

**Table.3. Details of Lactose Monohydrate**

| Synonyms                        | CapsuLac; GranuLac; Lactochem; lactosum monohydricum; Monohydrate; Pharmatose |
|---------------------------------|------------------------------------------------------------------------------|
| Chemical Name                   | O-b-D-Galactopyranosyl-(1→4)-a-D-glucopyranose monohydrate                    |
| Molecular Formula               | C12H22O11.H2O                                                                 |
| Molecular Weight                | 360.31                                                                        |
| Functional Category             | Dry powder inhaler carrier; lyophilization aid; tablet binder; tablet and capsule diluent; tablet and capsule filler. |
| Description                     | In the solid state, lactose appears as various isomeric forms, depending on the crystallization and drying conditions. Lactose occurs as white to off-white crystalline particles or powder. Lactose is odorless and slightly sweet-tasting; α-lactose is approximately 20% as sweet as sucrose, while β-lactose is 40% as sweet. |
| Density (bulk)                  | 0.57 (g/cm³)                                                                  |
| Density (tapped)                | 0.84 (g/cm³)                                                                  |
| Melting point                   | 201–202°C                                                                    |
| Moisture contents               | 4.5–5.5% w/w                                                                  |
| Solubility                      | Soluble in water; sparingly soluble in ethanol (95%) and ether; 40 g/100mL at 25°C for typical Sheffield Pharma Ingredients products. |
| Stability and Storage Conditions| Lactose may develop a brown coloration on storage, the reaction being accelerated by warm, damp conditions. Lactose should be stored in a well-closed container in a cool, dry place. |
| Incompatibilities               | A Maillard-type condensation reaction is likely to occur between lactose and compounds with a primary amine group to form brown, or yellow-brown-colored products. The Maillard interaction has also been shown to occur between lactose and secondary amine. Lactose is also incompatible with amino acids, amfetamines, and lisinopril. |
| Safety                          | Adverse reactions to lactose are largely due to lactose intolerance, which occurs in individuals with a deficiency of the enzyme lactase. |
| Regulatory Status               | GRAS listed.                                                                   |
**Table 4. Details of MCC**

| **Synonyms** | Avicel PH, Vivapur |
|--------------|-------------------|
| **Chemical Name** | Cellulose |
| **Molecular Formula** | $(C_6H_{10}O_5)_n$; Where $n = 220$ |
| **Molecular Weight** | 36 000 |
| **Functional Category** | Adsorbent, suspending agent, tablet and capsule diluents, tablet disintegrant. |
| **Description** | Microcrystalline cellulose is purified, partially depolymerized cellulose that occurs as a white, odorless, tasteless, crystalline powder composed of porous particles. |
| **Density (bulk)** | 0.32 g/cm³ for Avicel PH-101; 0.29 g/cm³ for Vivapur 101 |
| **Density (tapped)** | 0.478 g/cm³ |
| **Melting point** | 260–270°C |
| **Solubility** | Slightly soluble in 5% w/v sodium hydroxide solution, practically insoluble in water, dilute acids and most organic solvents. |
| **Stability and Storage Conditions** | Microcrystalline cellulose is a stable though hygroscopic material. The bulk material should be stored in a well-closed container in a cool, dry place. |
| **Incompatibilities** | Microcrystalline cellulose is incompatible with strong oxidizing agents. |
| **Safety** | Microcrystalline cellulose is widely used in oral pharmaceutical formulations and food products and is generally regarded as a relatively nontoxic and nonirritant material. Microcrystalline cellulose is not absorbed systemically following oral administration and thus has little toxic potential. Consumption of large quantities of cellulose may have a laxative effect, although this is unlikely to be a problem when cellulose is used as an excipient in pharmaceutical formulations. |
| **Regulatory Status** | GRAS listed. |

**Magnesium Stearate**

| **Synonyms** | Stearic acid, Dibasic magnesium stearate |
|--------------|--------------------------------------|
| **Chemical Name** | Octadecanoic acid magnesium salt |
| **Molecular Formula** | $C_{36}H_{76}MgO_4$ |
| **Molecular Weight** | 591.24 |
| **Functional Category** | Tablet and capsule lubricant. |
| **Description** | Magnesium stearate is a very fine, light white, precipitated or milled, impalpable powder of low bulk density, having a faint odor of stearic acid and a characteristic taste. The powder is greasy to the touch and readily adheres to the skin. |
| **Solubility** | Practically insoluble in ethanol, ethanol (95%), ether and water. Slightly soluble in warm benzene and warm ethanol (95%). |
| **Melting range** | 117–150 °C (commercial samples) 126–130 °C (high purity magnesium stearate). |
| **Stability and Storage Conditions** | Magnesium stearate is stable and should be stored in a well-closed container in a cool, dry place. |
| **Incompatibilities** | Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with strong oxidizing materials. Magnesium stearate cannot be used in products containing aspirin, some vitamins and most alkaloidal salts. |
| **Safety** | Magnesium stearate is widely used as a pharmaceutical excipient and is generally regarded as being nontoxic following oral administration. However, oral consumption of large quantities may produce a laxative effect or mucosal irritation. |
Table 6. Details of Triacetin

| Synonyms                  | Captex 500; E1518; glycerol triacetate; glyceryl triacetate |
|---------------------------|----------------------------------------------------------------|
| Chemical Name             | 1, 2, 3-Propanetriol triacetate                               |
| Molecular Formula         | C₉H₁₄O₆                                                        |
| Molecular Weight          | 218.21                                                         |
| Functional Category       | Humectant; plasticizer; solvent                                |
| Description               | Triacetin is a colourless, viscous liquid with a slightly fatty odour |
| Melting point             | -78°C                                                          |
| Stability and Storage     | Triacetin is stable and should be stored in a well-closed, non-metallic container, in a cool, dry place |
| Conditions               |                                                               |
| Incompatibilities         | Triacetin is incompatible with metals and may react with oxidizing agents. Triacetin may destroy rayon fabric |
| Safety                    | Triacetin is used in oral pharmaceutical formulations and is generally regarded as a relatively nontoxic and non-irritant material |
| Regulatory Status         | GRAS listed                                                    |

2. CONCLUSION

Alosetron is right now the main 5-HT3 receptor antagonist affirmed for the administration of serious IBS-D in ladies. A few clinical trials have demonstrated that alosetron viably treats the assortment of GI side effects, including fecal desperation, stool consistency and recurrence, and stomach pain and distress, and in addition enhances HRQoL in patients with IBS-D. Though the utilization of alosetron has been related with serious yet uncommon unfavourable conditions, the rate of these effects has basically stayed uncommon and stable and they have not brought about any death since alosetron was reintroduced in November 2002. Despite of these researches, it creates the impression that just the most extreme IBS cases are being treated with alosetron. Results in patients with IBS-D may be advanced through the precise assessment and diagnosis of IBS seriousness as it identifies with both GI symptomatology and affect on HRQoL. With such an appraisal, a proper and powerful treatment plan can be started to enhance side effects and facilitate the enduring identified with IBS.

REFERENCES

Ameen V.Z, Tong K and Pan H, The Risk Management Program (RiskMAP) is effective in mitigating serious outcomes of ischemic colitis and complications of constipation with marketed use of alosetron since reintroduction, Annual Meeting of the American College of Gastroenterology, Orlando, FL, USA, 2008.

Aragon G, Graham D.B, Borum M and Doman D.B, Probiotic therapy for irritable bowel syndrome, Gastroenterology & Hepatology, 6 (1), 2010, 39-44.

Bennet G and Talley N.J, Irritable bowel syndrome in elderly, Department of medicine, Nepean Hospital NSW, Australia, 2002.

Camilleri M and Anderson V, Current and Novel Therapeutic Options for Irritable Bowel Syndrome Management, Digestive and Liver Disease, 41, 2009, 854-862.

Caplan A, Walker L and Rasquin A, Validation of pediatric Rome 2 criteria for functional gastrointestinal disorder using the questionnaire on pediatric gastrointestinal symptoms, Journal of Pediatric Gastroenterology and Nutrition, 41, 2005, 305-316.

Ceremoni F, Aros S.D and Camilleri M, Efficacy of Alosetron in Irritable bowel syndrome, a Meta-analysis of randomized controlled trials, Neurogastroenterology and Motility, 15, 2003, 79-86.

Chang L, Chey W.D, Harris L, Olden K, Surawicz C, Schoenfeld P, Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data, Am J Gastroenterol, 101, 2006, 1069-1079.

Chumpitazi B.P, Bristol Stool Form Scale Reliability and Agreement Decreases When Determining Rome III Stool Form Designations, Neuro gastroenterology and Motility, 28 (11), 2016, 443–448.

Fred C, Drug for irritable bowel syndrome taken off the market, BMJ, 321 (7274), 2000, 1429-1432.
Horton R, Lotronex and the FDA, a fatal erosion of integrity, Lancet, 357, 2001, 1544–1545.

Hungin A.P.S, Chang L, Locke G.R, Dennis E.H and Barghouts V, Irritable bowel syndrome in the United States, Prevalence, symptoms pattern and impact, Aliment Pharmacol Ther, 21, 2005, 1365-1375.

Ladep, Nimzing G, Okeke, Edith N, Samaila, Adamu A, Irritable bowel syndrome among patients attending general outpatients clinics in jos, Nigeria, European Journal of Gastroenterology & Hepatology, 19 (9), 2007, 795-799.

Michael C, Pharmacology and clinical experience with alosetron, Ashley Publications Ltd., 9 (1), 2000, 147-159

Pourhoseingholi A, Increased rectal mucosal entero endocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, World Journal of Gastroenterology, 19 (23), 2013, 3520-3523.

Raymond C Rowe, Paul J Sheskey, Sian C Owen, Handbook of Pharmaceutical Excipients, Pharmaceutical Press, Edn 6, vol. 2, 2006, 389-430.